title: Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study.
abstract: OBJECTIVE
  To investigate the effect of intravenous hydralazine infusion on maternal nitric oxide (NO) levels.
  
  
  METHODS
  This pilot study comprised 40 (n = 40) gestations complicated with severe preeclampsia to whom maternal plasma NO levels were determined by chemiluminescence before and after hydralazine administration. Blood pressure values were concomitantly assessed.
  
  
  RESULTS
  After 20 min of intravenous hydralazine infusion blood pressure values decrease significantly in term and preterm gestations. This was accompanied by an overall significant decrease in mean plasma NO values (38.7 ± 12.9 to 35.4 ± 13.9 μmol/L, p < 0.05). Despite this, NO values decreased in 67.5% of cases (a 17.6% from baseline) and increased in 32.5% (a 14.8% from baseline) (p < 0.05 for both). Blood pressure decrease (%) was lower (systolic and diastolic) among those displaying a NO decrement than in the increment group. Interestingly, gestational age was higher in the group displaying decreased NO; however, this did not reach statistical significance (37.5 ± 2.7 vs. 35.9 ± 2.8 weeks, p = 0.08).
  
  
  CONCLUSIONS
  The results of this study fail to demonstrate a similar NO secretion after hydralazine infusion in women with severe preeclampsia.
authors.affiliation: Biomedical Center, Universidad Central del Ecuador, Quito, Ecuador. e_teran_uce@hotmail.com
authors.forename: Enrique
authors.initials: E
authors.lastname: Teran
authors.forename: Fernando
authors.initials: F
authors.lastname: Briones
authors.forename: Verónica
authors.initials: V
authors.lastname: Nicolalde
authors.forename: Sandra
authors.initials: S
authors.lastname: Vivero
authors.forename: Peter
authors.initials: P
authors.lastname: Chedraui
authors.forename: Faustino R
authors.initials: FR
authors.lastname: Pérez-López
mesh_terms: D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001724:Birth Weight; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage*; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D009569:Nitric Oxide / Q000096:biosynthesis / Q000097:blood*; D010865:Pilot Projects; D011225:Pre-Eclampsia / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D047928:Premature Birth; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D006830:Hydralazine; D009569:Nitric Oxide